Announced Fri, 26 Jun, 2026 · 13:09 IST

CFO Parth H Palera resigns from Deccan Health Care effective 25 June 2026

Cfo ResignedManagement Changes View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.3%Reaction day

₹13.37

prior close

₹13.38

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.3%+1.5% vs market

Healthcare Service Provider peers, median of 26sector-0.5%+1.8% vs sector

On the reaction day the stock moved 1.5 pts more than Nifty Microcap 250 and 1.8 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.8

10m

+0.8

15m

+0.8

30m

-2.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.3-0.3+1.5-0.5+1.8

Next day

+0.5+0.8-0.2-0.7+1.2

-6.5+0.9-7.4+0.1-6.6

-2.3+1.8-4.1+0.2-2.5

-0.1+1.5-1.6-1.5+1.4

+2.5+1.7+0.8+0.0+2.5

-4.6-1.1-3.5-1.2-3.4

15d

-2.8+1.0-3.8-1.9-0.8

-2.4+0.4-2.8-1.4-1.0

-3.4+6.4-9.7-1.0-2.3

-11.2+5.5-16.7-2.3-8.9

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 26Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Deccan Health Care Ltd informed BSE that its CFO and Key Managerial Personnel Mr. Parth H Palera resigned with immediate effect from close of business on 25 June 2026 to pursue a better professional opportunity. He also held the additional role of Administrative Executive cum Accountant. He will cease to be the KMP authorized for determining materiality of events under SEBI Listing Regulations. No successor has been announced yet.

Likely market impact

C-suite exit at a small-cap pharma company. Investors should watch for timely appointment of a new CFO and any disruption to financial reporting.